grant
SARS-CoV-2 immune responses in patients with lymphoma
NIHUS FederalResearch GrantFY20252019 novel corona virus2019 novel coronavirus2019-nCoV2019-nCoV vaccineATAC sequencingATAC-seqATACseqActivities of Daily LivingActivities of everyday lifeAntibodiesAntibody ResponseAntigensAssayAssay for Transposase-Accessible Chromatin using sequencingB blood cellsB cellB cell depletion therapyB cell directed therapyB cell targeted therapyB cell therapiesB cell therapyB cellsB-Cell CLLB-Cell Chronic Lymphocytic LeukemiaB-Cell Chronic Lymphogenous LeukemiaB-Cell Chronic Lymphoid LeukemiaB-Cell Lymphocytic LeukemiaB-Cell NHLB-Cell Non-Hodgkin's LymphomaB-Cell NonHodgkins LymphomaB-CellsB-LymphocytesB-Lymphocytic LeukemiaB-cellBioassayBiological AssayBloodBlood Reticuloendothelial SystemBlood SampleBlood specimenBooster ImmunizationCD4 CellsCD4 Positive T LymphocytesCD4 T cellsCD4 helper T cellCD4 lymphocyteCD4+ T-LymphocyteCD4-Positive LymphocytesCD8CD8 CellCD8 T cellsCD8 lymphocyteCD8+ T cellCD8+ T-LymphocyteCD8-Positive LymphocytesCD8-Positive T-LymphocytesCD8BCD8B1CD8B1 geneCITE sequencingCITE-seqCITEseqCOVID-19 immune responseCOVID-19 infectionCOVID-19 vaccinationCOVID-19 vaccineCOVID-19 virusCOVID-19 virus infectionCOVID19 infectionCOVID19 virusCancersCell BodyCell Mediated ImmunologyCell TherapyCell-Mediated ImmunityCellsCellular ImmunityCellular Indexing of Transcriptomes and Epitopes by SequencingCessation of lifeChromatinChronic B-Lymphocytic LeukemiaChronic Lymphatic LeukemiaChronic Lymphoblastic LeukemiaChronic Lymphocytic LeukemiaChronic Lymphogenous LeukemiaClinical DataCoV-2CoV2Combined Modality TherapyDataDeathDevelopmentDysfunctionEvolutionFunctional disorderGene TranscriptionGenerationsGenetic TranscriptionGerminoblastic SarcomaGerminoblastomaGoalsGrippeHistocompatibility ComplexHistocompatibility ComplicesImmune memoryImmune responseImmune systemImmunocompromisedImmunocompromised HostImmunocompromised PatientImmunologic MemoryImmunological MemoryImmunosuppressed HostImpairmentIndividualInfectionInfluenzaKnowledgeLYT3LabelLaboratoriesLifeLymph Node Reticuloendothelial SystemLymph node properLymphatic nodesLymphomaMaintenanceMajor Histocompatibility ComplexMajor Histocompatibility ComplicesMalignant LymphomaMalignant NeoplasmsMalignant TumorMemoryMentorshipMorbidityMorbidity - disease rateMultimodal TherapyMultimodal TreatmentNon-Hodgkin's LymphomaNonhodgkins LymphomaNucleocapsidPatientsPeptidesPhenotypePhysiopathologyPublishingRNA ExpressionRNA vaccineRNA-based vaccineRecommendationResearchReticulolymphosarcomaSARS corona virus 2SARS-CO-V2SARS-COVID-2SARS-CoV-2SARS-CoV-2 immune responseSARS-CoV-2 infectionSARS-CoV-2 vaccinationSARS-CoV-2 vaccineSARS-CoV2SARS-CoV2 infectionSARS-associated corona virus 2SARS-associated coronavirus 2SARS-coronavirus-2SARS-coronavirus-2 vaccineSARS-related corona virus 2SARS-related coronavirus 2SARSCoV2SamplingSecondary ImmunizationSerologySevere Acute Respiratory Coronavirus 2Severe Acute Respiratory Distress Syndrome CoV 2Severe Acute Respiratory Distress Syndrome Corona Virus 2Severe Acute Respiratory Distress Syndrome Coronavirus 2Severe Acute Respiratory Syndrome CoV 2Severe Acute Respiratory Syndrome CoV 2 vaccineSevere Acute Respiratory Syndrome-associated coronavirus 2Severe Acute Respiratory Syndrome-related coronavirus 2Severe acute respiratory syndrome associated corona virus 2Severe acute respiratory syndrome coronavirus 2Severe acute respiratory syndrome coronavirus 2 immune responseSevere acute respiratory syndrome coronavirus 2 infectionSevere acute respiratory syndrome coronavirus 2 vaccinationSevere acute respiratory syndrome coronavirus 2 vaccineSevere acute respiratory syndrome related corona virus 2Single cell seqStaining methodStainsT cell receptor repertoire sequencingT cell receptor sequencingT cell responseT-Cell LymphomaT-Cell Non-Hodgkin's LymphomaT-Cell NonHodgkins LymphomaT-Cell and NK-Cell Non-Hodgkin's LymphomaT-CellsT-LymphocyteT4 CellsT4 LymphocytesT8 CellsT8 LymphocytesTCR repertoire sequencingTCR sequencingTCR-seqTCRseqTechnologyTissue SampleTranscriptionVaccinatedVaccinationVaccineeVaccinesVariantVariationViralViral DiseasesVirusVirus DiseasesVulnerable PopulationsWuhan coronavirusadaptive immune responseanamnestic reactionanti-cancer immunotherapyanticancer immunotherapyantigen-specific T cellsassay for transposase accessible chromatin followed by sequencingassay for transposase accessible chromatin seqassay for transposase accessible chromatin sequencingassay for transposase-accessible chromatin with sequencingbooster dosebooster shotbooster vaccinationbooster vaccinecancer immunotherapycell based interventioncell mediated interventioncell mediated therapiescell-based therapeuticcell-based therapycellular indexing of transcriptomes and epitopes by single cell sequencingcellular therapeuticcellular therapychronic lymphoid leukemiacohortcombination therapycombined modality treatmentcombined treatmentcoronavirus disease 2019 immune responsecoronavirus disease 2019 infectioncoronavirus disease 2019 vaccinationcoronavirus disease 2019 vaccinecoronavirus disease 2019 viruscoronavirus disease-19 vaccinecoronavirus disease-19 viruscytokinedaily living functiondaily living functionalitydesigndesigningdevelopmentalfunctional abilityfunctional capacityhCoV19high riskhost responseimmune response to vaccinationimmune response to vaccinesimmune system responseimmune-based cancer therapiesimmunogenimmunoresponseimmunosuppressedimmunosuppressed patientimmunotherapy for cancerimmunotherapy of cancerimprovedinfected with COVID-19infected with COVID19infected with SARS-CoV-2infected with SARS-CoV2infected with coronavirus disease 2019infected with severe acute respiratory syndrome coronavirus 2insightintervention designleukemia treatmentleukemic therapylymph glandlymph nodeslymphnodesmRNA vaccinemRNA-based vaccinemalignancymalignant lymphocytemortalitymulti-modal therapymulti-modal treatmentnCoV vaccinenCoV-19 vaccinenCoV19 vaccinenCoV2neoplasm/cancernon-Hodgkins diseasenovelpathophysiologypatient populationpreventpreventingprogramsproliferation capabilityproliferation capacityproliferation potentialproliferative capabilityproliferative capacityproliferative potentialresponsesecondary immune responsesingle cell next generation sequencingsingle cell sequencingtherapeutic vaccinetherapy designthymus derived lymphocytetreatment designtreatment vaccinesvaccinate against COVID-19vaccinate against SARS-CoV-2vaccinate against coronavirus disease 2019vaccinate against severe acute respiratory syndrome coronavirus 2vaccinated individualvaccinated participantvaccinated patientvaccinated personvaccinated subjectvaccination against COVID-19vaccination against SARS-CoV-2vaccination against Severe acute respiratory syndrome coronavirus 2vaccination against coronavirus disease 2019vaccine against 2019-nCovvaccine against COVID-19vaccine against SARS-CoV-2vaccine against SARS-coronavirus-2vaccine against Severe Acute Respiratory Syndrome CoV 2vaccine against Severe acute respiratory syndrome coronavirus 2vaccine associated immune responsevaccine boostvaccine candidates against SARS-CoV-2vaccine efficacyvaccine for novel coronavirusvaccine for the treatmentvaccine for treatmentvaccine immune responsevaccine immunogenicityvaccine induced immune responsevaccine responsevaccine responsivenessvaccine-induced responsevaccines preventing COVIDvaccines to prevent COVIDviral infectionvirus infectionvirus-induced diseasevulnerable groupvulnerable individualvulnerable people
Description preview
Project Summary
Non-Hodgkin lymphoma and chronic lymphocytic leukemia (NHL/CLL) patients have immune system deficits
that arise from the cancer and are aggravated by lymphoma therapies, placing them at higher risk of morbidity
and mortality after infection with viruses like influenza and severe acute respiratory syndrome coronavirus 2…
🔒
Start 7-day free trial — $29.99/mo →Full details available on the Agency plan
Unlock the complete grant description, eligibility criteria, contract value, evaluation details and apply link — plus alerts, pipeline tracking, and CSV export.
Agency Plan
7-day free trialUnlock procurement & grants
Upgrade to access active tenders from World Bank, UNDP, ADB and more — with email alerts and pipeline tracking.
$29.99 / month
- 🔔Email alerts for new matching tenders
- 🗂️Track tenders in your pipeline
- 💰Filter by contract value
- 📥Export results to CSV
- 📌Save searches with one click